Centessa Pharmaceuticals (CNTA) Total Non-Current Liabilities (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Total Non-Current Liabilities data on file, last reported at $154.4 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $154.4 million, up 9.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $154.4 million (up 9.05% YoY), and the FY2025 annual result was $160.6 million, down 8.34% from the prior year.
• Total Non-Current Liabilities declined to $154.4 million in Q1 2026 per CNTA's latest filing, from $160.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $175.2 million in Q4 2024 and troughed at $101.0 million in Q2 2022.
• A 5-year average of $128.8 million and a median of $118.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities jumped 317.49% in 2022, then slipped 8.34% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $108.1 million in 2022, then rose by 14.64% to $124.0 million in 2023, then jumped by 41.34% to $175.2 million in 2024, then retreated by 8.34% to $160.6 million in 2025, then decreased by 3.87% to $154.4 million in 2026.
• Business Quant data shows CNTA's Total Non-Current Liabilities at $154.4 million in Q1 2026, $160.6 million in Q4 2025, and $146.7 million in Q3 2025.